Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging market, announces that further to the announcement of 15 February 2019, the Company has delivered and installed its latest research unit order for a 9820 Xenon Polariser system from the University of British Columbia https://www.ubc.ca/.
Polarean Imaging Plc
(“Polarean” or the “Company”)
New System Delivery and Installation
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that further to the announcement of 15 February 2019, the Company has delivered and installed its latest research unit order for a 9820 Xenon Polariser system from the University of British Columbia (“UBC”) https://www.ubc.ca/.
The UBC polariser is initially being installed at BC Children’s Hospital (http://www.bcchildrens.ca/) while construction proceeds on its ultimate site at UBC. BC Children’s is a major paediatric research and teaching hospital. This new unit will support their paediatric pulmonary disease research programme using hyperpolarised gas imaging. Their order was enabled by a grant from the Canada Foundation for Innovation (“CFI”) www.innovation.ca/about. Following delivery of this order, the total number of the Company’s polarisers that are either installed or on order is 25.
Richard Hullihen, CEO of Polarean, said: “We have now delivered and installed our latest polariser, which is a platform for the researchers at BC Children’s Hospital, expanding our paediatric research cluster which includes Cincinnati Children’s Hospital Medical Center and Toronto SickKids Hospital. We look forward to enabling their new discoveries in these critical projects and we welcome UBC to the group.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Enquiries:
| Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | |||
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR | |||
| Richard Morgan, Chairman | ||||
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 | |||
David Hignell, Soltan Tagiev (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) | ||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | |||
| Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 | |||
